Comparison of the mechanism of cytotoxicity of 2-chloro-9-(2-deoxy-2- fluoro-beta-D-arabinofuranosyl)adenine, 2-chloro-9-(2-deoxy-2-fluoro- beta-D-ribofuranosyl)adenine, and 2-chloro-9-(2-deoxy-2,2-difluoro- beta-D-ribofuranosyl)adenine in CEM cells.
In an effort to understand biochemical features that are important to the selective antitumor activity of 2-chloro-9-(2-deoxy-2-fluoro-beta-D-arabinofuranosyl)adenine [Cl-F( upward arrow)-dAdo], we evaluated the biochemical pharmacology of three structurally similar compounds that have quite different antitumor activities. Cl-F( upward arrow)-dAdo was 50-fold more potent as an inhibitor of CEM cell growth than were either 2-chloro-9-(2-deoxy-2-fluoro-beta-D-ribofuranosyl)adenine [Cl-F( downward arrow)-dAdo] or 2-chloro-9-(2-deoxy-2, 2-difluoro-beta-D-ribofuranosyl)adenine [Cl-diF( upward arrow downward arrow)-dAdo]. The compounds were similar as substrates of deoxycytidine kinase. Similar amounts of their respective triphosphates accumulated in CEM cells, and the rate of disappearance of these metabolites was also similar. Cl-F( upward arrow)-dAdo was 10- to 30-fold more potent in its ability to inhibit the incorporation of cytidine into deoxycytidine nucleotides than either Cl-F( downward arrow)-dAdo or Cl-diF( upward arrow downward arrow)-dAdo, respectively, which indicated that ribonucleotide reductase was differentially inhibited by these three compounds. Thus, the differences in the cytotoxicity of these agents toward CEM cells were not related to quantitative differences in the phosphorylation of these agents to active forms but can mostly be accounted for by differences in the inhibition of ribonucleotide reductase activity. Furthermore, the inhibition of RNA and protein synthesis by Cl-F( downward arrow)-dAdo and Cl-diF( upward arrow downward arrow)-dAdo at concentrations similar to those required for the inhibition of DNA synthesis can help explain the poor antitumor selectivity of these two agents because all cells require RNA and protein synthesis.
Southern Research Institute, Birmingham, Alabama 35205, USA. parker@sri.org
W B
WB
Parker
S C
SC
Shaddix
L M
LM
Rose
D S
DS
Shewach
L W
LW
Hertel
J A
JA
Secrist
J A
JA
Montgomery
L L
LL
Bennett
D000227:Adenine Nucleotides; D000970:Antineoplastic Agents / Q000494:pharmacology*; D001087:Arabinonucleosides / Q000494:pharmacology*; D002455:Cell Division / Q000187:drug effects; D000077866:Clofarabine; D004247:DNA / Q000096:biosynthesis / Q000187:drug effects; D003839:Deoxyadenosines / Q000494:pharmacology*; D003841:Deoxycytidine / Q000378:metabolism; D003842:Deoxycytidine Kinase / Q000037:antagonists & inhibitors / Q000302:isolation & purification / Q000378:metabolism; D004791:Enzyme Inhibitors / Q000494:pharmacology; D006801:Humans; D046911:Macromolecular Substances; D010766:Phosphorylation / Q000187:drug effects; D013379:Substrate Specificity; D014316:Tritium; D014407:Tumor Cells, Cultured
C117863:2-chloro-9-(2-deoxy-2,2-difluororibofuranosyl)adenine; C117864:2-chloro-9-(2-deoxy-2-fluororibofuranosyl)adenine; D000227:Adenine Nucleotides; D000970:Antineoplastic Agents; D001087:Arabinonucleosides; D003839:Deoxyadenosines; D004791:Enzyme Inhibitors; D046911:Macromolecular Substances; D003841:Deoxycytidine; D014316:Tritium; D000077866:Clofarabine; D004247:DNA; D003842:Deoxycytidine Kinase